ARISTOCORT
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARISTOCORT is an oral tablet small-molecule corticosteroid approved in 1957 by Astellas. The exact indication profile is not specified in available data, but as a legacy corticosteroid, it is used to treat inflammatory and autoimmune conditions. The mechanism of action involves glucocorticoid receptor binding to suppress inflammatory cytokine production.
LOE Approaching
As LOE approaches, brand team focus will shift from growth maintenance to managed decline and potential cost optimization strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ARISTOCORT offers limited career growth potential given the LOE approaching phase and minimal linked job openings. Roles are primarily defensive, focused on maintaining market share and managing generic competition rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on ARISTOCORT at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.